Krajina: Kanada
Jazyk: angličtina
Zdroj: Health Canada
FLUTICASONE PROPIONATE
PHARMASCIENCE INC
R03BA05
FLUTICASONE
125MCG
METERED-DOSE AEROSOL
FLUTICASONE PROPIONATE 125MCG
INHALATION
15G/50G
Prescription
ADRENALS
Active ingredient group (AIG) number: 0124685004; AHFS:
APPROVED
2020-08-06
_ _ _Page 1 of 57_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR PMS-FLUTICASONE HFA fluticasone propionate inhalation aerosol 50, 125, and 250 mcg/metered dose PR PMS-FLUTICASONE fluticasone propionate dry powder for inhalation 100, 250, and 500 mcg/blister Corticosteroid for Oral Inhalation PHARMASCIENCE INC. 6111 Royalmount Ave., Suite 100 Montréal, Canada H4P 2T4 www.pharmascience.com Date of Initial Approval: August 5, 2020 Date of Revision: May 25, 2021 Submission Control No: 251505 _pms-FLUTICASONE_ _ HFA and pms-FLUTICASONE- Product Monograph _ _Page 2 of 57_ TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. TABLE OF CONTENTS ..............................................................................................................2 PART I: HEALTH PROFESSIONAL INFORMATION ............................................................4 1 INDICATIONS ....................................................................................................................4 1.1 Pediatrics ........................................................................................................................4 1.2 Geriatrics ........................................................................................................................4 2 CONTRAINDICATIONS ..................................................................................................4 4 DOSAGE AND ADMINISTRATION .......................................................................................4 4.1 Dosing Considerations ...................................................................................................5 4.2 Recommended Dose and Dosage Adjustment ...............................................................5 4.4 Administration ...............................................................................................................7 4.5 Missed Dose ........................................................................................ Prečítajte si celý dokument